Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer.
Kalogirou C, Linxweiler J, Schmucker P, Snaebjornsson MT, Schmitz W, Wach S, Krebs M, Hartmann E, Puhr M, Müller A, Spahn M, Seitz AK, Frank T, Marouf H, Büchel G, Eckstein M, Kübler H, Eilers M, Saar M, Junker K, Röhrig F, Kneitz B, Rosenfeldt MT, Schulze A. Kalogirou C, et al. Among authors: kneitz b. Nat Commun. 2021 Aug 20;12(1):5066. doi: 10.1038/s41467-021-25325-9. Nat Commun. 2021. PMID: 34417456 Free PMC article.
Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients.
Moltzahn F, Karnes J, Gontero P, Kneitz B, Tombal B, Bader P, Briganti A, Montorsi F, Van Poppel H, Joniau S, Spahn M. Moltzahn F, et al. Among authors: kneitz b. Prostate Cancer Prostatic Dis. 2015 Mar;18(1):31-7. doi: 10.1038/pcan.2014.41. Epub 2014 Dec 23. Prostate Cancer Prostatic Dis. 2015. PMID: 25535100
The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Moris L, Battaglia A, van der Poel H, Walz J, Bossi A, De Meerleer G, Haustermans K, Van Poppel H, Spahn M, Joniau S. Tosco L, et al. Among authors: kneitz b. Prostate Cancer Prostatic Dis. 2017 Dec;20(4):407-412. doi: 10.1038/pcan.2017.29. Epub 2017 May 9. Prostate Cancer Prostatic Dis. 2017. PMID: 28485390
PAF1c links S-phase progression to immune evasion and MYC function in pancreatic carcinoma.
Gaballa A, Gebhardt-Wolf A, Krenz B, Mattavelli G, John M, Cossa G, Andreani S, Schülein-Völk C, Montesinos F, Vidal R, Kastner C, Ade CP, Kneitz B, Gasteiger G, Gallant P, Rosenfeldt M, Riedel A, Eilers M. Gaballa A, et al. Among authors: kneitz b. Nat Commun. 2024 Feb 16;15(1):1446. doi: 10.1038/s41467-024-45760-8. Nat Commun. 2024. PMID: 38365788 Free PMC article.
Critical Evaluation of a microRNA-Based Risk Classifier Predicting Cancer-Specific Survival in Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava.
Kotlyar MJ, Krebs M, Solimando AG, Marquardt A, Burger M, Kübler H, Bargou R, Kneitz S, Otto W, Breyer J, Vergho DC, Kneitz B, Kalogirou C. Kotlyar MJ, et al. Among authors: kneitz b. Cancers (Basel). 2023 Mar 26;15(7):1981. doi: 10.3390/cancers15071981. Cancers (Basel). 2023. PMID: 37046643 Free PMC article.
Ki-67, topoisomerase IIα and miR-221 have a limited prostate cancer risk stratification ability on a medium-term follow-up: results of a high-risk radical prostatectomy cohort.
Marra G, Oderda M, Calleris G, Marquis A, Peretti F, Zitella A, Moschini M, Sanchez-Salas R, Karnes RJ, Kneitz B, Spahn M, Pacchioni D, Gontero P. Marra G, et al. Among authors: kneitz b. Transl Androl Urol. 2022 Sep;11(9):1271-1281. doi: 10.21037/tau-21-628. Transl Androl Urol. 2022. PMID: 36217395 Free PMC article.
High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer.
Eckhardt C, Sbiera I, Krebs M, Sbiera S, Spahn M, Kneitz B, Joniau S, Fassnacht M, Kübler H, Weigand I, Kroiss M. Eckhardt C, et al. Among authors: kneitz b. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):484-490. doi: 10.1038/s41391-021-00431-3. Epub 2021 Jul 29. Prostate Cancer Prostatic Dis. 2022. PMID: 34326474 Free PMC article.
79 results